ChartRow logo
Data provided bySource: Twelve Data
JAZZ
$240.71+0.39%
as of close, Nov 17, 2026
☾ AH $240.71 +0.39%
Share this page

JAZZ financial statements

The full income statement, balance sheet, and cash-flow statement for Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +12.5%10Y CAGR +12.4%YoY +10.4%
$4.7B TTM$1.2B Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y n/mYoY n/m
$426M TTM−$413.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y n/mYoY n/m
$206M TTM−$483.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m10Y n/mYoY n/m
$3.15 TTM−$7.48 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

5Y CAGR +8.5%10Y CAGR +9.8%YoY +6.6%
$1.7B TTM$506.1M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Capital expenditure

5Y CAGR +31.4%10Y CAGR +5.0%YoY +6.6%
$70.8M TTM$16.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +8.0%10Y CAGR +10.1%YoY +6.6%
$1.6B TTM$489.9M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y +7.9%10Y −3.3%YoY +5.0%
65.3M TTM64.7M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Every JAZZ chart on Trends →

Shares outstanding (point-in-time)

2024-09 60.5M2024-12 60.7M2025-03 61.6M2025-06 60.7M2025-09 60.8M2025-12 61.6M2026-03 62.7M2026-06 64.9M2026-09 64.2M+6.2% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue4.27B+4.9%4.07B+6.1%3.83B+4.8%3.66B+18.3%3.09B+30.9%
Research & development783M-11.5%884M+4.0%850M+43.9%590M+16.7%506M+50.8%
Selling, general & administrative1.81B+30.6%1.39B+3.1%1.34B-5.2%1.42B-2.4%1.45B+69.9%
Amortization of intangibles655M+4.4%627M+3.1%608M+1.5%599M+14.0%526M+102.5%
Operating income-430M-160.0%717M+23.9%579M+983.0%-65.5M-138.5%170M-55.0%
Interest expense——32.8M+0.0%32.8M-63.5%89.9M+2.6%
Interest & investment income85.8M-19.3%106M+63.3%65.1M+466.1%11.5M+538.9%1.80M-83.8%
Equity-method income-732K+55.9%-1.66M+44.8%-3.01M+69.7%-9.92M-1289.5%-714K+75.9%
Pre-tax income-628M-233.5%470M+57.9%298M+179.9%-373M-230.4%-113M-141.0%
Income tax-272M-198.0%-91.4M+23.8%-120M+24.4%-159M-173.4%216M+544.8%
-356M-163.6%560M+35.0%415M+285.1%-224M+32.0%-330M-238.2%
Net income to common-356M-163.6%560M+35.0%415M+285.1%-224M+32.0%-330M-238.2%
-$5.84-167.5%$8.65+41.8%$6.10+270.4%-$3.58+35.1%-$5.52-230.8%
EPS (basic)-$5.84-164.5%$9.06+38.3%$6.55+283.0%-$3.58+35.1%-$5.52-229.0%
Weighted-avg shares (basic)61.0M-1.4%61.8M-2.3%63.3M+1.2%62.5M+4.8%59.7M+7.1%
Weighted-avg shares (diluted)61.0M-7.6%66.0M-8.4%72.1M+15.2%62.5M+4.8%59.7M+5.6%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
4.17B-10.0%4.63B+34.7%3.44B+31.8%2.61B-0.2%2.61B-8.0%
Cash & equivalents1.39B-42.3%2.41B+60.2%1.51B+70.9%881M+49.0%591M-44.1%
Cash & short-term investments
2.44B————
Accounts receivable831M+15.9%717M+1.6%706M+8.3%651M+15.6%563M+42.1%
Inventory417M-13.2%480M-19.5%597M-16.4%714M-33.4%1.07B+1024.5%
Prepaid expenses153M-14.0%177M-4.3%185M+101.8%91.9M-30.1%131M+110.5%
Other current assets324M+23.8%262M-18.5%321M+20.1%267M+5.9%252M+65.5%
11.7B-2.9%12.0B+5.4%11.4B+5.2%10.8B-11.9%12.3B+88.2%
Operating lease right-of-use58.9M+9.9%53.6M-18.0%65.3M-10.9%73.3M-15.3%86.6M-33.0%
Goodwill1.83B+6.6%1.72B-2.1%1.75B+3.6%1.69B-7.4%1.83B+90.7%
Intangible assets4.43B-6.9%4.76B-12.2%5.42B-6.5%5.79B-19.0%7.15B+225.8%
Deferred tax assets869M+55.1%560M+17.2%478M+27.0%376M+20.9%311M+22.0%
Other non-current assets99.0M-13.5%114M+69.7%67.5M+22.4%55.1M+35.1%40.8M+58.7%
2.24B+115.9%1.04B-32.4%1.54B+64.7%933M+15.3%809M+23.8%
Accounts payable122M+56.8%77.9M-24.2%103M+13.2%90.8M-9.5%100M+272.2%
Accrued liabilities1.03B+13.5%911M+14.7%794M-1.2%803M+20.6%666M+88.9%
Deferred revenue——0.00-100.0%463K-77.9%2.09M-17.8%
Short-term & current debt1.03B+3222.3%31.0M-94.9%605M+1851.5%31.0M+0.0%31.0M-87.4%
Current lease liability14.3M-0.4%14.3M-24.6%19.0M+22.3%15.6M+1.3%15.4M+6.2%
Finance lease liability (current)439K-2.0%448K+4.7%428K+12.3%381K-6.2%406K
Long-term debt4.33B-28.8%6.08B+19.0%5.11B-10.3%5.69B-5.4%6.02B+225.6%
Deferred revenue (non-current)———0.00-100.0%463K-80.0%
Non-current lease liability50.9M+30.7%38.9M-34.3%59.2M-17.6%71.8M-17.6%87.2M-37.7%
Operating lease liability (total)65.2M+22.3%53.3M-31.9%78.2M-10.5%87.4M-14.8%103M-33.6%
Finance lease liability (total)3.88M-22.6%5.01M-8.4%5.47M-2.2%5.59M-16.2%6.67M
Finance lease liability3.44M-24.6%4.56M-9.5%5.04M-3.3%5.21M-16.9%6.27M
Deferred tax liabilities595M-12.2%677M-20.2%848M-10.2%944M-27.4%1.30B+897.4%
Other non-current liabilities124M+43.6%86.6M-17.3%105M-1.9%107M-8.7%117M+15.7%
4.32B+5.5%4.09B+9.5%3.74B+21.1%3.09B-22.2%3.97B+8.3%
Common stock0.00-100.0%6.00K+0.0%6.00K+0.0%6.00K+0.0%6.00K+0.0%
Additional paid-in capital4.24B+8.4%3.91B+5.8%3.70B+6.4%3.48B-1.6%3.53B+34.2%
Retained earnings646M-42.7%1.13B+28.3%879M+19.8%734M-11.6%830M-28.4%
Accumulated other comprehensive income-569M+40.0%-948M-12.5%-842M+25.2%-1.13B-181.1%-400M-198.0%
Total equity incl. non-controlling4.32B+5.5%4.09B+9.5%3.74B+21.1%3.09B-22.2%3.97B+8.3%
Total liabilities & equity11.7B-2.9%12.0B+5.4%11.4B+5.2%10.8B-11.9%12.3B+88.2%
Common shares issued61.4M+1.3%60.6M-2.6%62.3M-1.5%63.2M+2.6%61.6M+9.7%
Common shares outstanding61.4M+1.3%60.6M-2.6%62.3M-1.5%63.2M+2.6%61.6M+9.7%
Shares outstanding (cover)61.6M+1.4%60.7M-2.6%62.3M-1.6%63.3M+2.6%61.7M+9.6%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
1.36B-2.9%1.40B+27.8%1.09B-14.1%1.27B+63.4%779M-13.5%
Depreciation & amortization696M+5.5%660M+3.3%639M+1.5%629M+13.9%552M+98.6%
Intangible amortization655M+4.4%627M+3.1%608M+1.5%599M+14.0%526M+102.5%
Share-based compensation291M+17.4%248M+9.3%227M+2.2%222M+17.5%189M+56.2%
Deferred income taxes-445M-113.6%-208M+19.9%-260M+11.0%-292M-522.3%69.2M+150.5%
Change in receivables106M+403.3%21.1M-59.3%51.9M-42.4%90.1M-2.8%92.7M+140.0%
Change in inventory86.0M+88.9%45.5M+239.4%13.4M-73.0%49.6M+1.6%48.9M+60.0%
Change in payables39.9M+298.5%-20.1M-309.0%9.60M+185.6%-11.2M-119.7%57.0M+401.1%
-1.51B-197.1%-508M-211.7%-163M+63.5%-446M+91.4%-5.21B-417.2%
Capital expenditure58.8M+54.3%38.1M+58.9%24.0M-17.5%29.0M+5.1%27.6M+84.2%
Free cash flow1.30B-4.5%1.36B+27.1%1.07B-14.1%1.24B+65.5%751M-15.1%
Acquisitions0.000.000.000.00-100.0%6.23B
Purchases of investments1.83B+40.2%1.31B+234.6%390M+539.1%61.0M+127.6%26.8M-98.9%
Sales/maturities of investments1.36B+60.9%845M+213.0%270M+350.0%60.0M-94.5%1.09B-37.6%
-873M-4357.1%20.5M+106.7%-305M+42.3%-529M-113.3%3.97B+651.9%
Long-term debt issued0.000.000.000.00-100.0%1.47B
Long-term debt repaid0.000.000.000.000.00
Common stock issued0.000.000.000.000.00
Common stock repurchased125M-59.9%311M+15.4%270M+499457.4%54.0K0.00-100.0%
Dividends paid0.000.000.000.000.00
FX effect on cash6.55M+491.3%-1.68M-247.3%1.14M+118.3%-6.22M-94.0%-3.21M-957.5%
Net change in cash-1.02B-212.6%907M+45.1%625M+115.4%290M+162.2%-466M-210.9%
Interest paid249M-21.0%315M-5.5%333M+23.1%271M+95.8%138M+225.6%
Income taxes paid122M+6.0%115M-35.4%178M+87.9%94.7M-65.1%271M+19.6%
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap10.5B+39.9%7.48B-3.4%7.74B-22.8%10.0B+27.5%7.87B-15.4%
P/E—13.4×-86.2%96.9×——
P/S2.5×+33.4%1.8×-9.9%2.0×-27.1%2.8×+10.1%2.5×-35.4%
P/B2.4×+32.6%1.8×-17.7%2.2×-39.3%3.7×+84.2%2.0×-21.9%
P/FCF8.1×+46.5%5.5×-11.6%6.2×-33.1%9.3×-11.2%10.5×-0.3%
Earnings yield—7.5%+625.3%1.0%——
FCF yield12.4%-31.7%18.2%+13.1%16.1%+49.4%10.7%+12.6%9.5%+0.3%
Source filing10-K10-K10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Bruce C. Cozadd $18.8M / $24.1MRenee D. Gala $19.2M / $29.8M$38M$53.9M$7.1M$103.00$124.75
FY2024Bruce C. Cozadd$15.5M$17.3M$4.7M$74.61$93.49
FY2023Bruce C. Cozadd$15.3M−$2.5M$4.2M$74.52$94.03
FY2022Bruce C. Cozadd$17.3M$26.3M$5M$96.52$89.90
FY2021Bruce C. Cozadd$15.7M$4.9M$4.5M$77.19$100.02
FY2020Bruce C. Cozadd$12.6M$19.6M$4.1M——

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: JAZZ’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all JAZZ filings on SEC EDGAR → Not investment advice.